By Fineline Cube 
US-Irish firm Medtronic plc (NYSE: MDT) has submitted twin 510(k) applications to the U.S. Food and Drug Administration (FDA) for its interoperable diabetes management system. The system includes the MiniMed 780G Insulin Pump as an ACE (Alternate Controller Enabled) device and the SmartGuard™ Interoperable Automated Glycemic Controller (iAGC) algorithm. This marks a significant step in advancing integrated diabetes care solutions.
System Components and Innovation
The MiniMed 780G Insulin Pump, configured as an ACE device, is designed to work seamlessly with third-party continuous glucose monitoring (CGM) systems. The SmartGuard™ iAGC algorithm enhances automated glycemic control, offering patients improved management of their blood glucose levels. This interoperability represents a breakthrough in personalized diabetes care.
Partnership with Abbott
This regulatory filing integrates Abbott’s (NYSE: ABT) FreeStyle Libre 7+ CGM with Medtronic’s insulin delivery technology. Under their strategic partnership announced in August 2023, Abbott will supply customized CGM sensors exclusively compatible with Medtronic’s smart dosing systems through 2030. This collaboration underscores Medtronic’s commitment to expanding its diabetes management portfolio and improving patient outcomes.-Fineline Info & Tech